Tax Season is Here! Save 15% on H&R Block Online
iconAll times are GMT -4. The time now is 12:37 AM. | Search:

» StockRants Stock Forum » Public Stock Forums » US Stock Picks » Strong Buy: IG (Mcap $69M) 3x Products launched// 11x Products awaiting FDA approval



Reply
 
Thread Tools Search this Thread
Old 08-16-2013, 11:26 AM   Nav to Top  #1
Biohero
Senior Trader
 
Biohero's Avatar
 
Join Date: Jan 2012
Location: Frankfurt
Posts: 284
Favorites: Aapl celg onxx
Rep Power: 114
Reputation: 36
Biohero is on a distinguished road
Default IG (Mcap $69M) 3x Products launched// 11x Products awaiting FDA approval

Unkown Gem with Brutally Upside Potential .. Good Luck Folks

Summary :

Laughable Market Cap of $69 M
Cash for 12 Months >>> Profitability before Year End
3 Products launched in USA since December 2012
Fourth Product will enter the Market in this Quarter
11 Products under review by FDA many of these will get FDA approval within 12 Months
68% of all Shares Outstanding held by Insiders & Institutions and still buying more
Small Float of only ~12 Million Shares

I think targets of $8-12 within 1-2 years is more realistic than Roth Capitals $3.50 .

Ticker ( IG )

Market Cap : $69 M
Cash : $1.3 M
Price : $1.60

Shares Out : 43 M
Float : 12 M


Massive buying by Institutions
http://data.cnbc.com/quotes/IG/tab/8

and buying by Management
http://www.secform4.com/insider-trading/352998.htm


IGI’s President and Chief Executive Officer, Jason Grenfell-Gardner, stated, “I am extremely pleased with the progress we have made to obtain IGI’s current market position in our first three IGI labeled topical pharmaceutical products. We are ready to launch our fourth product, econazole nitrate cream 1%, which we acquired earlier this year, during the third quarter of 2013 pending final FDA approval of our site transfer. We have expanded our IGI label customer base for our existing product lines, and we continue to explore opportunities to potentially expand our product portfolio. Our formulation and manufacturing contract services revenue continued to grow, and has increased 10% over 2012 year to date.” Mr. Grenfell-Gardner continued, “Our research and development team has filed three ANDAs in 2013, one in January, one in April, and one in July, which brings our total filings pending with the US FDA to 11. Our team is committed to our plan to file at least six ANDAs in 2013. We remain on track for our target to at least double our 2012 total revenue and achieve profitability in 2013


----

Roth starts IGI Labs at buy
August 7, 2013

Roth Capital Partners has initiated coverage of IGI Laboratories (NYSE MKT:IG) with a “buy” rating and 12-month price target of $3.50, saying the impetus for the rating is “expectations for the company’s internal proprietary generic pipeline to come to fruition and drive sustainable earnings profitability.”

Analyst Scott Henry writes that IGI Labs has 11 ANDAs at the FDA, and “we expect approvals starting in late 2013/early 2014. We view this pipeline as the engine for sustainable profitability in 2014-plus.”

In addition, he said IGI is currently launching two new products – Synalar and econazole nitrate – that could have combined annual peak revenue potential approaching $10-million. These compounds could take the company to earnings breakeven, he added.

“We believe that topicals are among the most attractive segments for an emerging generics company, with higher barriers to entry and better pricing,” he said. “We believe that this further makes IGI Labs a target for industry consolidation.”
Biohero is offline   1 thumbs up / 0 thumbs down. Rate this post Yes | No Reply With Quote
Old 08-20-2013, 10:14 AM   Nav to Top  #2
Biohero
Senior Trader
 
Biohero's Avatar
 
Join Date: Jan 2012
Location: Frankfurt
Posts: 284
Favorites: Aapl celg onxx
Rep Power: 114
Reputation: 36
Biohero is on a distinguished road
Thread Starter
Default

Breakout to over $2 imminent ...

Upcoming Milestones 2013 includes :

1) US Market launch of fourth Product Econazole this Quarter
2) Another 3 ANDA filings in 2H
3) Achieve Profitability in 2013

http://www.barchart.com/opinions/stocks/IG

http://www.stoxline.com/quote.php?symbol=ig
Biohero is offline   Rate this post Yes | No Reply With Quote
Old 11-01-2013, 08:52 AM   Nav to Top  #3
Biohero
Senior Trader
 
Biohero's Avatar
 
Join Date: Jan 2012
Location: Frankfurt
Posts: 284
Favorites: Aapl celg onxx
Rep Power: 114
Reputation: 36
Biohero is on a distinguished road
Thread Starter
Default

More good news out today ... Now they have 13 Products awaiting FDA approval .GL

IGI Laboratories, Inc. Announces Thirteenth ANDA Submission
http://finance.yahoo.com/news/igi-la...123000375.html



Great Earnings (hits Breakeven) ,Great Management , Full Product Pipeline with 12 Products awaiting FDA aaproval everything looks fantastic on this Company. GL

One of the best and underpriced Play in the Biotech Sector .Gl

Ticker ( IG )

Market Cap : $86 M
Cash : $2.3 M
Price : $2

Shares Out : 43 M .....(31 Million Shares held by Big Investors)
Float : 11 M

IGI's President and Chief Executive Officer, Jason Grenfell-Gardner, stated, "Our team has done a tremendous job this quarter. This quarter marks the fifth consecutive quarter of top line growth. Our net loss is rapidly approaching break even for the first time at IGI in over twenty-two quarters. We have solidified our market position in our first three IGI labeled topical pharmaceutical products, and we have successfully launched our fourth product, econazole nitrate cream 1%, which we acquired earlier this year, during the third quarter of 2013." Mr. Grenfell-Gardner continued, "Our research and development team has now filed four ANDAs in 2013, which brings our total filings pending with the US FDA to twelve. Based on current IMS data, the addressable market for our pipeline of twelve ANDAs, pending approval at the US FDA is estimated at over $300 million. Our team is committed to our plan to file at least six ANDAs in 2013. We believe we are on track to at least double our 2012 total revenue and achieve profitability in 2013."
Biohero is offline   Rate this post Yes | No Reply With Quote
Reply

Similar Threads
Thread Thread Starter Forum Replies Last Post
Strong Buy: ACRX (Mcap $54 M) 3x PRODUCTS IN PHASE 3 // RESULTS THIS MONTH =500% Potential !!! Biohero US Stock Picks 0 11-11-2012 04:47 PM
Strong Buy: (IPCI) 6 Drugs awaiting FDA Approval (Mcap 48 M) !!! Biohero US Stock Picks 0 02-03-2012 12:09 PM
Strong Buy: $IVAX - FDA approval this Q (Mcap 16 M) Low Float 5 M biotechmaster US Penny Stock Picks 0 01-07-2011 08:41 AM
Strong Buy: FDA approval within 4 Weeks (Mcap 24 M$) Shares Out 11 M biotechmaster US Stock Picks 4 12-13-2010 06:44 AM
Dividend: $UVFT kills Swine Flu, FDA approved products!!!! $$ monsterpennies US Penny Stock Picks 0 12-24-2009 02:05 PM


Thread Tools Search this Thread
Search this Thread:

Advanced Search

Posting Rules
You may not post new threads
You may not post replies
You may not post attachments
You may not edit your posts

BB code is On
Smilies are On
[IMG] code is On
HTML code is On